RESUMO
Aprotic Li-O2 batteries are a promising energy storage technology, however severe side reactions during cycles lead to their poor rechargeability. Herein, highly reactive singlet oxygen (1O2) is revealed to generate in both the discharging and charging processes and is deterimental to battery stability. Electron-rich triphenylamine (TPA) is demonstrated as an effective quencher in the electrolyte to mitigate 1O2 and its associated parasitic reactions, which has the tertiary amine and phenyl groups to manifest excellent electrochemical stability and chemical reversibility. It reacts with electrophilic 1O2 to form a singlet complex during cycles, and it then quickly transforms to a triplet complex through nonradiative intersystem crossing (ISC). This efficiently accelerates the conversion of 1O2 to the ground-state triplet oxygen to eliminate its derived side reactions, and the regeneration of TPA. These enable the Li-O2 battery with obviously reduced overvoltages and prolonged lifetime for over 310 cycles when coupled with a RuO2 catalyst. This work highlights the ISC mechanism to quench 1O2 in Li-O2 battery.
RESUMO
Aprotic lithium-oxygen (Li-O2) batteries have gained extensive interest in the past decade, but are plagued by slow reaction kinetics and induced large-voltage hysteresis. Herein, we use a plasmonic heterojunction of Au nanoparticle (NP)-decorated C3N4 with nitrogen vacancies (Au/NV-C3N4) as a bifunctional catalyst to promote oxygen cathode reactions of the visible light-responsive Li-O2 battery. The nitrogen vacancies on NV-C3N4 can adsorb and activate O2 molecules, which are subsequently converted to Li2O2 as the discharge product by photogenerated hot electrons from plasmonic Au NPs. While charging, the holes on Au NPs drive the reverse decomposition of Li2O2 with a reduced applied voltage. The discharge voltage of the Li-O2 battery with Au/NV-C3N4 is significantly raised to 3.16 V under illumination, exceeding its equilibrium voltage, and the decreased charge voltage of 3.26 V has good rate capability and cycle stability. This is ascribed to the plasmonic hot electrons on Au NPs pumped from the conduction bands of NV-C3N4 and the prolonged carrier life span of Au/NV-C3N4 This work highlights the vital role of plasmonic enhancement and sheds light on the design of semiconductors for visible light-mediated Li-O2 batteries and beyond.
RESUMO
Non-aqueous Li-O2 batteries have aroused considerable attention because of their ultrahigh theoretical energy density, but they are severely hindered by slow cathode reaction kinetics and large overvoltages, which are closely associated with the discharge product of Li2O2. Herein, hexagonal conductive metal-organic framework nanowire arrays of nickel-hexaiminotriphenylene (Ni-HTP) with quadrilateral Ni-N4 units are synthesized to incorporate Ru atoms into its skeleton for NiRu-HTP. The atomically dispersed Ru-N4 sites manifest strong adsorption for the LiO2 intermediate owing to its tunable d-band center, leading to its high local concentration around NiRu-HTP. This favors the formation of film-like Li2O2 on NiRu-HTP with promoted electron transfer and ion diffusion across the cathode-electrolyte interface, facilitating its reversible decomposition during charge. These allow the Li-O2 battery with NiRu-HTP to deliver a remarkably reduced charge/discharge polarization of 0.76 V and excellent cyclability. This work will enrich the design philosophy of electrocatalysts for regulation of kinetic behaviors of oxygen redox.
RESUMO
Aprotic Li-O2 batteries have attracted extensive attention in the past decade owing to their high theoretical energy density; however, they are obstructed by the sluggish reaction kinetics at the cathode and large voltage hysteresis. We regulate the spin state of partial Ni2+ metal centers (t2g 6 eg 2 ) of conductive nickel catecholate framework (NiII -NCF) nanowire arrays to high-valence Ni3+ (t2g 6 eg 1 ) for NiIII -NCF. The spin-state modulation enables enhanced nickel-oxygen covalency in NiIII -NCF, which facilitates electron exchange between the Ni sites and oxygen adsorbates and accelerates the oxygen redox kinetics. Upon discharging, the high affinity of Ni3+ sites with the intermediate LiO2 promotes formation of nanosheet-like Li2 O2 in the void space among NiIII -NCF nanowires. The Li-O2 battery based on NiIII -NCF offers remarkably reduced discharge/charge voltage gaps, superior rate capability, and a long cycling stability of over 200 cycles. This work highlights the importance of electron spin state on the redox kinetics and will provide insight into electronic structure regulation of electrocatalysts for Li-O2 batteries and beyond.
RESUMO
Li-O2 batteries have aroused considerable interest in recent years, however they are hindered by high kinetic barriers and large overvoltages at cathodes. Herein, a step-scheme (S-scheme) junction with hematite on carbon nitride (Fe2 O3 /C3 N4 ) is designed as a bifunctional catalyst to facilitate oxygen redox for a visible-light-involved Li-O2 battery. The internal electric field and interfacial Fe-N bonding in the heterojunction boost the separation and directional migration of photo-carriers to establish spatially isolated redox centers, at which the photoelectrons on C3 N4 and holes on Fe2 O3 remarkably accelerate the discharge and charge kinetics. These enable the Li-O2 battery with Fe2 O3 /C3 N4 to present an elevated discharge voltage of 3.13â V under illumination, higher than the equilibrium potential 2.96â V in the dark, and a charge voltage of 3.19â V, as well as superior rate capability and cycling stability. This work will shed light on rational cathode design for metal-O2 batteries.
RESUMO
Li-O2 batteries are considered the ultimate energy storage technology for their potential to store large amounts of electrical energy in a cost-effective and simple platform. Large overpotentials for the formation and oxidation of Li2O2 during discharging and charging have thus far confined this technology to a scientific curiosity. Herein, we consider the role of catalytic intervention in the reversibility of the cathode reactions and find that semiconducting metal-organic polymer nanosheets composed of cobalt-tetramino-benzoquinone (Co-TABQ) function as a bifunctional catalyst that facilitates the kinetics of the cathode reactions under visible light. Upon discharging, we report that O2 is first adsorbed on the Co atoms of Co-TABQ and accepts electrons under illumination from the dz2 and dxz orbitals of Co atoms in the π2p* orbitals, which facilitates reduction to LiO2. The LiO2 is further shown to undergo a second reduction to the discharge product of Li2O2. In the reverse charge, the holes generated in the dz2 orbitals of Co are mobilized under the action of the applied voltage to enable the fast decomposition of Li2O2 to O2 and Li+. Under illumination, the Li-O2 battery exhibits respective discharge and charge voltages of 3.12 and 3.32 V for a round-trip efficiency of 94.0%. Our findings imply that the orbital interaction of metal ions with ligands in Co-TABQ nanosheets dictates the light harvesting and oxygen electrocatalysis for the Li-O2 battery.
RESUMO
Qingdai, a traditional Chinese medicine (TCM) used for the treatment of chronic myeloid leukemia (CML) with good efficacy, has been used in China for decades. However, due to the complexity of traditional Chinese medicinal compounds, the pharmacological mechanism of Qingdai needs further research. In this study, we investigated the pharmacological mechanisms of Qingdai in the treatment of CML using network pharmacology approaches. First, components in Qingdai that were selected by pharmacokinetic profiles and biological activity predicted putative targets based on a combination of 2D and 3D similarity measures with known ligands. Then, an interaction network of Qingdai putative targets and known therapeutic targets for the treatment of chronic myeloid leukemia was constructed. By calculating the 4 topological features (degree, betweenness, closeness, and coreness) of each node in the network, we identified the candidate Qingdai targets according to their network topological importance. The composite compounds of Qingdai and the corresponding candidate major targets were further validated by a molecular docking simulation. Seven components in Qingdai were selected and 32 candidate Qingdai targets were identified; these were more frequently involved in cytokine-cytokine receptor interaction, cell cycle, p53 signaling pathway, MAPK signaling pathway, and immune system-related pathways, which all play important roles in the progression of CML. Finally, the molecular docking simulation showed that 23 pairs of chemical components and candidate Qingdai targets had effective binding. This network-based pharmacology study suggests that Qingdai acts through the regulation of candidate targets to interfere with CML and thus regulates the occurrence and development of CML.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Medicamentos de Ervas Chinesas/química , Medicamentos de Ervas Chinesas/farmacologia , Ontologia Genética , Humanos , Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia , Simulação de Acoplamento Molecular , Reprodutibilidade dos Testes , Transdução de Sinais/genéticaRESUMO
BACKGROUND: The clinicopathological and prognostic values of the cancer stem cell marker aldehyde dehydrogenase 1 (ALDH1) in ovarian cancer (OC) remain unknown. The aim of our meta-analysis was to evaluate ALDH1's association with clinicopathological characteristics and its prognostic significance in patients with OC. MATERIALS AND METHODS: PubMed, Embase, and China Biology Medicine were systematically searched for eligible studies (up to October 2017). Pooled odds ratios (ORs) or hazard ratios (HRs) with 95% CIs were used to evaluate the association of ALDH1 expression with clinicopathological features and survival outcomes. RESULTS: A total of 17 papers (18 studies) that included 2,531 patients with OC were analyzed. The results showed a significant association between increasing ALDH1 expression and International Federation of Gynecology and Obstetrics stage (OR 2.02, 95% CI 1.16-3.52), lymph node metastasis (OR 1.91, 95% CI 1.01-3.61), and distant metastasis (OR 5.43, 95% CI 1.44-20.42) in OC. However, no significant correlation was found between increasing ALDH1 expression and age (OR 0.90, 95% CI 0.25-3.28), tumor size (OR 1.13, 95% CI 0.75-1.71), tumor location (OR 0.69, 95% CI 0.22-2.13), ascite status (OR 0.74, 95% CI 0.49-1.11), resistance status (OR 0.70, 95% CI 0.14-3.51), or clinicopathological type (OR 1.14, 95% CI 0.69-1.86). Moreover, a high ALDH1 expression was significantly associated with overall survival (HR 1.56, 95% CI 1.21-2.02) but not with disease-free survival (HR 1.38, 95% CI 0.99-1.93). CONCLUSION: The meta-analysis indicates that increasing ALDH1 predicts poor prognosis and clinicopathological characteristics in OC. Future studies are needed to explore tailored treatments that directly target ALDH1 for the improvement of survival in OC.
RESUMO
BACKGROUND: Endocrine therapy is the cornerstone treatment for patients with hormone receptor-positive advanced breast cancer. We aimed to assess the effectiveness of various first-line endocrine monotherapies or combinations to determine the optimal sequence in a network meta-analysis. MATERIALS AND METHODS: We searched PubMed, EMBASE, and the Cochrane Library for randomized controlled trials (RCTs) from inception up to November 21, 2017. We included only RCTs that assessed the effectiveness of the following treatments as a monotherapy or in combination as the first-line treatment: tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, palbociclib, and ribociclib. The results were presented with pooled odds ratio or hazard ratio (HR), and 95% credible interval (CrI). The primary outcomes were objective response rate (ORR) and progression-free survival/time to progression. RESULTS: A total of 16 eligible articles (14 RCTs) involving 6,602 patients treated with 10 different first-line endocrine therapies were assessed in our network meta-analysis. Palbociclib plus letrozole was superior to anastrozole, letrozole, exemestane, fulvestrant 500 mg, and anastrozole plus fulvestrant (loading dose) (HR=0.44, 95% CrI: 0.33-0.58; HR=0.56, 95% CrI: 0.45-0.68; HR=0.45, 95% CrI: 0.32-0.61; HR=0.58, 95% CrI: 0.42-0.81; HR=0.50, 95% CrI: 0.37-0.68; respectively). However, there is no significant advantage compared with ribociclib plus letrozole (HR=1.00, 95% CrI: 0.72-1.39). In terms of ORR, ribociclib plus letrozole is more effective than palbociclib plus letrozole (odds ratio=1.30, 95% CrI: 0.83-2.02). CONCLUSION: Palbociclib plus letrozole and ribociclib plus letrozole might be the optimal first-line endocrine therapeutic choices for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer due to a longer progression-free survival/time to progression and a more efficacious ORR.
RESUMO
BACKGROUND: Chronic myelocytic leukemia is a disease that threatens both adults and children. Great progress has been achieved in treatment but protein-protein interaction networks underlining chronic myelocytic leukemia are less known. OBJECTIVE: To develop a protein-protein interaction network for chronic myelocytic leukemia based on gene expression and to predict biological pathways underlying molecular complexes in the network. MATERIALS AND METHODS: Genes involved in chronic myelocytic leukemia were selected from OMIM database. Literature mining was performed by Agilent Literature Search plugin and a protein-protein interaction network of chronic myelocytic leukemia was established by Cytoscape. The molecular complexes in the network were detected by Clusterviz plugin and pathway enrichment of molecular complexes were performed by DAVID online. RESULTS AND DISCUSSION: There are seventy-nine chronic myelocytic leukemia genes in the Mendelian Inheritance In Man Database. The protein-protein interaction network of chronic myelocytic leukemia contained 638 nodes, 1830 edges and perhaps 5 molecular complexes. Among them, complex 1 is involved in pathways that are related to cytokine secretion, cytokine-receptor binding, cytokine receptor signaling, while complex 3 is related to biological behavior of tumors which can provide the bioinformatic foundation for further understanding the mechanisms of chronic myelocytic leukemia.